singledos
decongest
versu
placebo
studi
compar
singl
dose
nasal
decongest
placebo
effect
test
minut
hour
dose
seven
studi
report
subject
symptom
score
nasal
congest
none
report
overal
patient
wellb
howev
pool
possibl
due
larg
divers
measur
report
symptom
congest
two
studi
record
advers
event
studi
use
oral
decongest
show
statist
differ
number
advers
event
treatment
group
versu
placebo
group
multidos
decongest
versu
placebo
nine
studi
compar
multipl
dose
nasal
decongest
placebo
five
report
primari
outcom
subject
symptom
score
nasal
congest
one
studi
use
topic
decongest
none
report
overal
patient
wellb
subject
measur
congest
significantli
better
treatment
group
compar
placebo
approxim
three
hour
last
dose
smd
confid
interv
ci
p
grade
lowqual
evid
howev
smd
indic
small
clinic
effect
pool
base
two
studi
one
oral
one
topic
therefor
unabl
assess
effect
oral
topic
decongest
separ
seven
studi
report
advers
event
six
oral
one
topic
decongest
metaanalysi
show
statist
differ
number
advers
event
treatment
group
per
compar
placebo
group
per
odd
ratio
advers
event
treatment
group
ci
p
grade
lowqual
evid
result
remain
consid
studi
use
oral
decongest
ci
p
grade
lowqual
evid
unabl
draw
conclus
effect
singledos
nasal
decongest
due
limit
evid
avail
multipl
dose
nasal
decongest
current
evid
suggest
may
small
posit
effect
subject
measur
nasal
congest
adult
common
cold
howev
clinic
relev
small
effect
unknown
insuffici
goodqual
evid
draw
firm
conclus
due
small
number
studi
use
topic
nasal
decongest
also
unabl
draw
conclus
effect
oral
versu
topic
decongest
nasal
decongest
seem
increas
risk
advers
event
adult
short
term
effect
safeti
nasal
decongest
children
clinic
relev
small
effect
adult
yet
determin
want
find
nasal
decongest
use
alon
eas
nasal
congest
symptom
peopl
cold
cold
although
seriou
common
ill
respons
mani
visit
famili
doctor
day
lost
work
school
cold
symptom
includ
runni
nose
sore
throat
sneez
last
two
week
cure
cold
treatment
eas
symptom
mani
peopl
use
overthecount
medicin
nasal
decongest
treat
cold
symptom
howev
prim
ari
outcom
e
subject
sym
ptom
score
hour
af
ter
dose
rct
oral
insuf
f
icient
data
pool
result
pseudoephedrin
eccl
latt
tavern
phenylpropanolam
ine
cohen
prim
ari
outcom
e
overal
patient
wellb
hour
af
ter
dose
studi
report
secondari
outcom
e
advers
event
two
singledos
trial
report
advers
event
gronborg
tavern
use
oral
decongest
tavern
pseudoephedrin
versu
placebo
report
advers
event
either
treatm
ent
placebo
group
includ
gronborg
norephedrin
versu
placebo
result
etaanalysi
crossov
studi
design
use
sever
event
per
patient
report
rct
oral
insuf
f
icient
data
pool
result
norephedrin
gronborg
pseudoephedrin
tavern
common
cold
viral
natur
afflict
individu
age
often
necessit
utilis
overthecount
prescript
medic
complementari
intervent
simasek
often
caus
rhinoviru
peopl
typic
experi
rhinorrhoea
sneez
headach
nasal
congest
cough
fatigu
pharyng
eccl
despit
common
cold
seriou
condit
substanti
impact
term
time
lost
work
school
well
money
spent
prescript
overthecount
medic
heikkinnenn
usa
common
cold
contribut
million
miss
day
school
million
absenc
work
annual
includ
day
miss
due
care
ill
children
pappa
australia
upper
respiratori
tract
infect
nasal
congest
pharyng
cough
constitut
consult
gener
practic
fri
usa
million
visit
famili
physician
annual
due
common
cold
total
econom
impact
common
cold
reach
around
usd
billion
annual
fendrick
nasal
congest
one
uncomfort
symptom
experienc
common
cold
fri
cure
common
cold
therefor
symptomat
therapi
treatment
option
nasal
decongest
wide
utilis
symptomat
relief
adult
children
administ
oral
topic
form
del
mar
decongest
may
contain
pseudoephedrin
phenylephrin
oxymetazolin
xylometazolin
nasal
decongest
avail
tablet
nasal
spray
drop
mostli
avail
overthecount
without
restrict
eccl
recommend
given
children
age
six
year
np
medicinewis
due
risk
rebound
congest
stop
use
decongest
advis
peopl
use
decongest
longer
five
day
nasal
decongest
mainli
act
local
may
system
effect
hypertens
common
side
effect
includ
headach
nausea
insomnia
dizzi
np
medicinewis
peopl
take
topic
nasal
ophthalm
decongest
quickli
develop
tachyphylaxi
rapid
decreas
respons
drug
repeat
dose
short
period
time
longterm
use
therefor
recommend
sinc
agent
lose
effect
day
previou
review
consid
safeti
efficaci
therapi
indic
includ
season
perenni
allerg
rhiniti
chronic
rhiniti
common
cold
influenza
dolanski
mani
market
treatment
common
cold
exist
may
consist
multipl
activ
agent
claim
decongest
antisecretori
anticough
action
heat
humidifi
air
one
type
treatment
intervent
mechan
action
includ
liquefi
mucu
dri
therebi
allow
clear
effect
also
work
heat
steam
kill
cold
viru
may
present
mucu
howev
routin
recommend
insuffici
evid
use
singh
corticosteroid
also
use
treatment
common
cold
recent
review
hayward
intranas
ipratropium
bromid
review
found
effect
reduc
rhinorrhoea
ineffect
reduc
nasal
congest
albalawi
cochran
review
salin
nasal
irrig
report
limit
evid
efficaci
reliev
symptom
nasal
secret
nasal
congest
upper
respiratori
tract
infect
king
combin
medic
also
studi
overal
recoveri
report
combin
antihistamin
decongest
analges
proven
effect
compar
placebo
de
sutter
modest
effect
oral
antihistaminedecongest
combin
oral
decongestantanalges
combin
oral
antihistaminedecongestantanalges
combin
nasal
congest
oral
analges
combin
seem
effect
symptom
nasal
congest
sinc
medic
common
cold
alreadi
previous
research
review
focu
nasal
decongest
assess
efficaci
shortand
longterm
safeti
nasal
decongest
use
monotherapi
allevi
symptom
common
cold
adult
children
criteria
consid
studi
review
includ
rct
clusterrct
randomis
crossov
studi
compar
nasal
decongest
placebo
exclud
quasirct
adult
children
age
either
gender
common
cold
characteris
defin
symptom
upper
respiratori
tract
infect
urti
elig
inclus
includ
particip
symptom
seven
day
prior
start
studi
exclud
studi
anoth
upper
respiratori
condit
influenza
sinus
rhiniti
diagnos
oral
topic
nasal
decongest
versu
placebo
oral
spray
appropri
includ
trial
use
topic
oral
nasal
decongest
administ
aqueou
spray
drop
dri
powder
tablet
capsul
focus
nasal
decongest
work
stimul
alphaadrenerg
receptor
upper
respiratori
tract
blood
vessel
lead
vasoconstrict
wicker
exclud
studi
report
combin
intervent
warm
humidifi
air
steam
aromat
vapour
inhal
corticosteroid
intervent
use
menthol
primari
outcom
subject
symptom
score
nasal
congest
selfreport
score
congest
overal
patient
wellb
score
selfreport
object
measur
nasal
airway
resist
nar
advers
event
exampl
dri
mucou
membran
rebound
congest
complic
exampl
sinus
otiti
media
lower
respiratori
tract
infect
time
full
recoveri
time
return
school
work
use
search
strategi
outlin
appendix
search
medlin
central
combin
medlin
search
strategi
cochran
highli
sensit
search
strategi
identifi
randomis
trial
medlin
lefebvr
appendix
adapt
search
strategi
search
embas
appendix
cinahl
appendix
lilac
appendix
web
scienc
appendix
languag
public
restrict
search
wwwclinicaltrialsgov
wwwanzctrorgau
identifi
complet
ongo
trial
juli
review
refer
list
contact
research
field
identifi
relev
studi
contact
manufactur
nasal
decongest
unpublish
studi
review
base
publish
protocol
ta
two
review
author
ld
nm
independ
review
appli
inclus
exclus
criteria
titl
abstract
identifi
search
retriev
full
text
insuffici
inform
titl
abstract
exclud
studi
three
review
author
ld
nm
lg
review
fulltext
articl
ensur
two
review
author
independ
judg
articl
consult
fourth
review
author
mlvd
discrep
two
author
issu
resolv
discuss
review
author
blind
inform
articl
journal
titl
author
articl
result
record
select
process
suffici
detail
complet
prisma
flow
diagram
figur
moher
characterist
exclud
studi
tabl
impos
languag
restrict
three
review
author
ld
nm
lg
independ
extract
data
includ
articl
use
predesign
data
extract
form
fourth
author
mlvd
assist
reach
consensu
data
entri
differ
extract
follow
data
first
author
public
year
journal
number
age
gender
distribut
patient
includ
trial
case
definit
symptom
measur
type
dosag
durat
rout
administr
nasal
decongest
result
primari
secondari
outcom
paper
provid
suffici
inform
either
studi
detail
result
contact
author
possibl
three
review
author
ld
nm
lg
independ
assess
risk
bia
resolv
disagr
discuss
arbit
mlvd
assess
random
sequenc
gener
alloc
conceal
blind
particip
personnel
relev
blind
outcom
assessor
incomplet
outcom
data
dropoutselect
outcom
report
potenti
sourc
bia
judg
potenti
sourc
bia
high
low
unclear
provid
quot
studi
report
togeth
justif
judgement
risk
bia
tabl
summaris
risk
bia
judgement
across
differ
studi
domain
list
report
risk
bia
use
risk
bia
tool
cochran
handbook
systemat
review
intervent
higgin
report
continu
data
standardis
mean
differ
smd
subject
object
measur
congest
measur
differ
scale
smd
adjust
differ
measur
scale
enabl
data
differ
score
system
pool
absolut
mean
differ
divid
standard
deviat
sd
dichotom
outcom
report
odd
ratio
or
smd
or
gener
revman
softwar
revman
calcul
confid
interv
ci
estim
analys
outcom
individu
particip
trial
unit
randomis
level
analysi
ie
individu
particip
clusterrct
plan
make
adjust
take
account
impact
cluster
outlin
cochran
handbook
systemat
review
intervent
higgin
trial
includ
one
treatment
arm
similar
differ
dose
nasal
decongest
combin
data
treatment
arm
similar
compar
group
control
group
recommend
cochran
handbook
systemat
review
intervent
section
tabl
higgin
studi
use
crossov
design
report
result
separ
includ
metaanalysi
unabl
obtain
addit
data
studi
author
mani
studi
quit
old
author
could
contact
therefor
possibl
compar
studi
use
intentiontotreat
itt
analysi
assum
miss
data
repres
unsuccess
outcom
report
itt
analysi
ontreat
analysi
sensit
analysi
assess
potenti
impact
miss
data
overal
effect
treatment
assess
heterogen
two
way
first
explor
presenc
heterogen
face
valu
compar
popul
group
intervent
outcom
across
studi
case
clear
face
valu
heterogen
report
outcom
studi
systemat
review
pool
result
obviou
heterogen
use
statist
test
cochran
q
test
statist
determin
presenc
level
statist
heterogen
outcom
higgin
consid
statist
repres
import
heterogen
possibl
explor
caus
statist
heterogen
use
subgroup
sensit
analys
specifi
priori
would
carri
metaanalysi
heterogen
greater
much
variat
result
particularli
inconsist
direct
effect
identifi
studi
outcom
measur
therefor
possibl
assess
report
bia
use
funnel
plot
describ
section
cochran
handbook
systemat
review
intervent
stern
analys
singledos
multidos
studi
separ
well
combin
clinic
expect
singl
multidos
nasal
decongest
would
similar
effect
although
may
long
last
case
singl
dose
therefor
combin
measur
singl
multidos
studi
three
hour
dose
includ
result
studi
met
inclus
criteria
report
select
outcom
metaanalysi
calcul
summari
weight
ci
dichotom
secondari
outcom
use
invers
varianc
studi
result
weight
standardis
result
studi
uniform
scale
look
continu
outcom
case
use
smd
express
size
intervent
effect
studi
rel
variabl
observ
studi
plan
calcul
number
need
treat
benefit
nntb
addit
benefici
outcom
use
summari
averag
control
event
rate
describ
relev
studi
howev
possibl
studi
assess
improv
nasal
congest
continu
scale
perform
fixedeffect
metaanalys
randomeffect
metaanalys
compar
two
model
report
differ
model
throughout
analys
use
randomeffect
model
final
report
defin
minim
clinic
import
differ
measur
subject
improv
nasal
congest
therefor
use
smd
guid
howev
smd
difficult
interpret
sever
option
avail
reexpress
smd
everi
method
benefit
pitfal
review
decid
use
rule
thumb
effect
size
guid
repres
small
effect
moder
effect
larg
effect
describ
section
cochran
handbook
systemat
review
intervent
stern
creat
summari
find
tabl
use
follow
outcom
subject
symptom
score
nasal
congest
overal
patient
wellb
advers
event
use
five
grade
consider
studi
limit
consist
effect
imprecis
indirect
public
bia
assess
qualiti
bodi
evid
relat
studi
contribut
data
metaanalys
prespecifi
outcom
atkin
includ
follow
comparison
singledos
decongest
versu
placebo
multidos
decongest
versu
placebo
dose
versu
placebo
use
method
recommend
describ
section
chapter
cochran
handbook
systemat
review
intervent
higgin
use
gradeprogdt
softwar
gradeprogdt
justifi
decis
downgrad
upgrad
qualiti
studi
use
footnot
made
comment
aid
reader
understand
review
necessari
decid
priori
suffici
data
avail
would
conduct
follow
subgroup
analys
explor
differenti
treatment
effect
children
age
year
versu
other
age
year
topic
versu
oral
nasal
decongest
decid
priori
perform
sensit
analys
assess
impact
heterogen
overal
outcom
pool
estim
metaanalysi
gradual
remov
singl
trial
investig
extent
contribut
heterogen
also
use
sensit
analys
assess
impact
risk
bia
overal
pool
estim
first
pool
studi
low
risk
bia
gradual
ad
studi
assess
high
risk
bia
result
base
publish
data
inform
studi
present
characterist
includ
studi
characterist
exclud
studi
characterist
studi
await
classif
characterist
ongo
studi
retriev
record
duplic
remov
search
electron
databas
central
medlin
embas
cinahl
lilac
web
scienc
base
screen
titl
abstract
exclud
record
assess
full
text
remain
articl
elig
figur
exclud
studi
base
full
text
two
studi
yet
classifi
two
studi
ongo
reason
exclus
exclud
studi
shown
characterist
exclud
studi
tabl
includ
refer
rct
eccl
publish
full
paper
well
abstract
intervent
consist
singl
dose
n
akerlund
cohen
ferguson
gronborg
latt
tavern
multipl
dose
n
nasal
decongest
bye
eccl
eccl
eccl
eccl
jawad
latt
reineck
sperber
intervent
includ
treatment
arm
combin
therapi
eg
pseudoephedrin
plu
paracetamol
howev
review
focus
effect
nasal
decongest
therefor
includ
treatment
arm
consid
combin
therapi
includ
trial
randomis
placebocontrol
except
one
jawad
trial
doubleblind
fourteen
rct
parallelgroup
studi
one
crossov
design
trial
includ
gronborg
includ
trial
involv
particip
includ
treatment
group
well
receiv
combin
therapi
particip
receiv
combin
therapi
drug
eg
paracetamol
exclud
total
number
particip
studi
conduct
unit
state
cohen
sperber
tavern
remain
studi
conduct
univers
gronborg
sperber
hospit
set
akerlund
cohen
set
unclear
two
studi
cohen
reineck
particip
six
trial
recruit
commun
via
poster
advertis
eccl
eccl
gronborg
jawad
latt
tavern
one
advertis
student
magazin
gronborg
two
trial
recruit
male
undergo
militari
train
akerlund
staff
chariti
foundat
bye
recruit
procedur
unclear
seven
trial
cohen
eccl
eccl
ferguson
latt
reineck
sperber
one
except
studi
includ
adult
particip
reineck
cutoff
studi
year
age
akerlund
cohen
eccl
eccl
eccl
gronborg
jawad
latt
latt
tavern
five
studi
provid
age
rang
bye
cohen
eccl
ferguson
sperber
trial
mean
age
year
akerlund
eccl
ferguson
gronborg
jawad
latt
sperber
mean
age
year
year
respect
tavern
bye
six
trial
provid
mean
age
cohen
eccl
eccl
eccl
latt
reineck
reineck
studi
includ
younger
peopl
particip
older
year
howev
mean
age
includ
particip
provid
thirteen
studi
clearli
defin
cutoff
time
sinc
onset
common
cold
akerlund
cohen
eccl
eccl
eccl
eccl
ferguson
gronborg
jawad
latt
latt
reineck
tavern
ten
studi
use
cutoff
durat
less
three
day
akerlund
cohen
eccl
eccl
eccl
eccl
gronborg
latt
latt
reineck
three
studi
use
cutoff
less
five
day
ferguson
jawad
tavern
one
studi
count
total
number
cold
period
year
specifi
durat
onset
symptom
enrol
studi
bye
anoth
experiment
induc
common
cold
via
intranas
rhinoviru
challeng
sperber
durat
followup
vari
one
day
six
singledos
studi
measur
effect
nasal
decongest
day
thu
followup
one
day
akerlund
cohen
ferguson
gronborg
latt
tavern
nine
trial
use
pseudoephedrin
bye
eccl
eccl
eccl
jawad
latt
latt
sperber
tavern
three
investig
oxymetazolin
akerlund
ferguson
reineck
other
use
xylometazolin
eccl
phenylpropanolamin
cohen
norephedrin
gronborg
howev
us
food
drug
administr
fda
issu
public
health
advisori
recommend
phenylpropanolamin
also
known
norephedrin
consid
safe
overthecount
use
ask
drug
manufactur
voluntarili
discontinu
market
product
contain
phenylpropanolamin
fda
consequ
phenylpropanolamin
longer
avail
decongest
countri
therefor
exclud
cohen
gronborg
metaanalys
seven
studi
use
pseudoephedrin
gener
administ
multipl
dose
bye
eccl
eccl
eccl
jawad
latt
sperber
use
oral
tablet
except
eccl
sperber
use
granul
sachet
oral
capsul
respect
remain
six
studi
use
pseudoephedrin
four
use
singl
dose
medic
akerlund
cohen
ferguson
gronborg
four
studi
use
topic
decongest
akerlund
eccl
ferguson
reineck
see
tabl
overview
seven
rct
report
nasal
airway
resist
nar
primari
outcom
akerlund
cohen
eccl
eccl
gronborg
latt
tavern
exclud
trial
ten
trial
exclud
studi
particip
symptom
nasal
congest
obstruct
reason
common
cold
eg
allerg
rhiniti
akerlund
ash
bailey
bend
bend
castellano
connel
pritchard
tzachev
zumpft
exclud
five
studi
due
lack
randomis
anderson
anonym
katrana
mcelhenney
smith
three
due
lack
placebo
control
group
dorn
fox
meurman
four
combin
therapi
use
report
cohen
de
paula
neve
rumiantsev
weisberg
reason
includ
symptom
durat
six
month
brom
measur
predefin
outcom
hummel
winther
identifi
two
ongo
trial
commerci
fund
doubleblind
rct
involv
particip
common
cold
use
nasal
decongest
parallelgroup
studi
enter
european
clinic
trial
regist
studi
investig
chang
nasal
conduct
particip
age
year
decongest
xylometazolin
inform
expect
end
date
studi
provid
multicentr
studi
began
novemb
involv
respons
nasal
congest
sever
children
age
six
year
decongest
pseudoephedrin
expect
complet
date
april
howev
chang
may
two
studi
await
classif
commerci
fund
doubleblind
rct
involv
respons
nasal
congest
particip
age
year
common
cold
nasal
decongest
xylometazolin
pseudoephedrin
although
studi
complet
unabl
find
publish
result
assess
includ
trial
use
six
specif
domain
detail
cochran
handbook
systemat
review
intervent
risk
bia
tool
higgin
result
assess
shown
studi
figur
summaris
figur
detail
includ
studi
present
characterist
includ
studi
overal
judgement
unclear
due
lack
detail
provid
trial
report
exampl
clear
detail
descript
method
sequenc
gener
alloc
conceal
blind
often
miss
mani
studi
also
pharmaceut
compani
fund
unknown
signific
deem
one
studi
high
risk
six
domain
jawad
studi
blind
therefor
assess
high
risk
blind
domain
assess
seven
studi
low
risk
domain
author
referenc
randomis
schedul
method
sequenc
gener
describ
detail
bye
cohen
eccl
eccl
latt
latt
tavern
exampl
treatment
randomis
random
number
tabl
block
four
latt
assess
remain
eight
studi
unclear
risk
domain
method
random
sequenc
gener
describ
akerlund
eccl
eccl
ferguson
gronborg
jawad
reineck
sperber
method
alloc
conceal
poorli
describ
insuffici
detail
provid
enabl
definit
judgement
conceal
achiev
assess
five
studi
low
risk
alloc
conceal
domain
bye
cohen
eccl
eccl
latt
exampl
possibl
distinguish
combin
product
monotherapi
placebo
appear
tast
notic
smell
eccl
assess
remain
studi
unclear
risk
none
provid
method
alloc
conceal
text
akerlund
eccl
eccl
ferguson
gronborg
jawad
latt
reineck
sperber
tavern
assess
nine
studi
low
risk
domain
blind
particip
key
studi
personnel
ensur
unlik
blind
could
broken
bye
cohen
eccl
eccl
eccl
eccl
gronborg
latt
tavern
exampl
randomis
code
broken
data
includ
delay
advers
event
alloc
tavern
assess
five
studi
unclear
risk
insuffici
inform
provid
permit
judgement
risk
akerlund
ferguson
latt
reineck
sperber
assess
remain
studi
high
risk
blind
jawad
assess
two
studi
low
risk
domain
state
method
blind
outcom
assess
eccl
gronborg
assess
studi
unclear
risk
insuffici
inform
method
blind
outcom
assess
permit
judgement
akerlund
bye
cohen
eccl
eccl
eccl
ferguson
latt
latt
reineck
sperber
tavern
assess
remain
studi
high
risk
blind
jawad
assess
studi
low
risk
domain
particip
includ
discontinu
account
text
author
clearli
indic
number
remain
particip
per
treatment
group
akerlund
bye
cohen
eccl
eccl
ferguson
gronborg
latt
sperber
tavern
assess
five
studi
unclear
risk
eccl
eccl
jawad
latt
reineck
number
remain
particip
treatment
group
could
ascertain
assess
studi
low
risk
select
report
studi
report
intend
outcom
akerlund
cohen
eccl
eccl
eccl
ferguson
gronborg
jawad
latt
latt
sperber
tavern
assess
three
studi
high
risk
select
report
bia
bye
eccl
reineck
bye
report
signific
result
detail
eccl
report
nac
rather
nar
eccl
assess
four
studi
low
risk
potenti
sourc
bia
evid
pharmaceut
compani
fund
sourc
bia
identifi
studi
akerlund
cohen
jawad
latt
studi
posit
score
indic
better
nasal
patenc
wherea
studi
neg
score
reflect
better
function
transform
neg
score
eg
multipli
comparison
higher
score
reflect
better
function
studi
could
combin
one
studi
includ
one
treatment
arm
four
differ
dose
nasal
decongest
combin
data
treatment
arm
similar
compar
group
control
group
akerlund
heterogen
greater
analys
test
report
differ
use
fixedeffect
randomeffect
model
appli
randomeffect
model
final
model
analys
randomeffect
model
gener
wider
confid
interv
ci
fixedeffect
model
higgin
present
result
singl
multidos
studi
separ
well
dosag
combin
outcom
evalu
effect
nasal
decongest
compar
placebo
approxim
three
hour
last
dose
chose
timefram
three
hour
clinic
expect
singl
multidos
nasal
decongest
would
similar
effect
although
may
long
last
case
singl
dose
furthermor
multidos
studi
measur
nasal
decongest
effect
approxim
three
hour
last
dose
discuss
result
comparison
singl
multidos
studi
avail
outcom
otherwis
refer
result
singl
multidos
comparison
separ
furthermor
multidos
studi
also
report
outcom
singl
dose
comparison
result
multipl
dose
includ
otherwis
studi
would
count
twice
possibl
also
present
result
studi
use
oral
topic
decongest
separ
combin
six
trial
singledos
studi
akerlund
cohen
ferguson
gronborg
latt
tavern
two
use
topic
decongest
akerlund
ferguson
four
use
oral
decongest
cohen
gronborg
latt
tavern
two
studi
assess
effect
treatment
minut
cohen
tavern
studi
use
oral
decongest
unabl
pool
result
cohen
exclud
metaanalys
cohen
estim
smd
treatment
placebo
statist
signific
favour
treatment
group
smd
ci
particip
cohen
oral
decongest
smd
ci
particip
tavern
oral
decongest
smd
correspond
larg
small
effect
respect
three
studi
measur
effect
nasal
decongest
subject
one
hour
dose
akerlund
cohen
tavern
three
studi
report
effect
nasal
decongest
compar
placebo
two
hour
treatment
cohen
latt
tavern
akerlund
cohen
also
report
effect
nasal
decongest
compar
placebo
four
hour
dose
akerlund
use
topic
decongest
cohen
use
oral
decongest
unabl
pool
result
exclud
cohen
metaanalys
studi
report
differ
outcom
measur
mean
mean
differ
md
neither
akerlund
smd
ci
particip
topic
decongest
cohen
smd
ci
particip
oral
decongest
show
statist
signific
differ
treatment
placebo
group
furthermor
studi
smd
correspond
small
clinic
effect
akerlund
use
topic
decongest
also
report
effect
singl
dose
nasal
decongest
seven
hour
dose
differ
treatment
placebo
group
particip
statist
signific
smd
ci
particip
akerlund
topic
decongest
gronborg
singledos
studi
use
oral
decongest
gronborg
use
crossov
design
therefor
result
includ
metaanalys
gronborg
report
two
hour
observ
period
dose
mean
score
subject
nasal
congest
better
treatment
group
compar
placebo
p
particip
result
report
ferguson
oral
decongest
includ
metaanalys
insuffici
detail
provid
standardis
result
clear
nar
measur
ferguson
report
nar
improv
treatment
group
p
control
group
p
studi
base
particip
abl
pool
result
eccl
sperber
topic
oral
decongest
respect
studi
provid
mean
score
subject
nasal
congest
pool
smd
statist
signific
favour
treatment
group
smd
ci
particip
two
studi
analysi
howev
smd
correspond
small
clinic
effect
differ
studi
use
oral
topic
decongest
signific
p
major
statist
heterogen
confirm
statist
nevertheless
use
randomeffect
model
chang
result
judg
level
evid
low
qualiti
pool
result
base
two
studi
imprecis
possibl
risk
bia
due
unclear
report
sperber
studi
report
mean
score
latt
studi
report
md
therefor
unabl
pool
result
studi
differ
subject
congest
treatment
versu
placebo
group
statist
signific
smd
ci
particip
sperber
oral
decongest
smd
ci
particip
latt
oral
decongest
bye
eccl
includ
metaanalys
insuffici
detail
provid
standardis
result
bye
particip
report
statist
signific
improv
subject
nasal
congest
treatment
group
end
day
one
howev
result
subject
nasal
congest
provid
day
two
three
unclear
subject
nasal
congest
treatment
group
compar
control
group
eccl
particip
report
statist
signific
differ
treatment
placebo
auc
va
hour
p
hour
p
last
dose
threeday
period
statist
signific
improv
mean
differ
nasal
congest
score
treatment
compar
placebo
eccl
use
topic
decongest
studi
differ
treatment
placebo
statist
signific
smd
correspond
moder
clinic
effect
smd
ci
particip
eccl
topic
decongest
three
studi
report
declin
mean
subject
symptom
score
nasal
congest
pool
effect
statist
signific
smd
ci
particip
three
studi
analysi
howev
smd
correspond
small
effect
eccl
use
topic
decongest
sperber
tavern
use
oral
decongest
differ
studi
use
oral
topic
decongest
signific
p
major
statist
heterogen
confirm
statist
use
randomeffect
model
chang
result
judg
evid
moder
qualiti
due
possibl
risk
bia
studi
use
oral
decongest
consid
sperber
tavern
differ
treatment
placebo
longer
statist
signific
smd
ci
particip
two
studi
analysi
latt
latt
report
auc
subject
nasal
congest
pool
effect
small
statist
signific
smd
ci
particip
two
studi
analysi
major
statist
heterogen
confirm
statist
mean
nasal
congest
auc
use
randomeffect
model
chang
result
judg
evid
low
qualiti
possibl
risk
bia
due
unclear
report
imprecis
none
studi
includ
metaanalys
primari
outcom
measur
report
intentiontotreat
itt
analys
eccl
latt
latt
sperber
tavern
eccl
mean
subject
score
nasal
congest
significantli
better
treatment
group
compar
placebo
eccl
randomis
particip
five
peopl
dose
analys
reason
exclus
provid
studi
particip
exclud
analysi
unabl
perform
rhinomanometri
latt
incomplet
data
latt
infect
wild
type
rhinoviru
withdrew
person
reason
sperber
unabl
complet
studi
tavern
eccl
use
topic
decongest
differ
treatment
placebo
statist
signific
smd
correspond
moder
clinic
effect
smd
ci
particip
includ
trial
report
outcom
object
measur
nar
test
minut
hour
dose
similar
subject
measur
nar
unabl
pool
result
therefor
report
result
time
point
detail
studi
cohen
object
measur
immedi
effect
nasal
decongest
versu
placebo
minut
administr
assess
mean
differ
nar
estim
smd
small
differ
treatment
placebo
group
statist
signific
smd
ci
particip
studi
use
oral
decongest
two
studi
object
assess
effect
oral
decongest
treatment
minut
cohen
tavern
studi
estim
smd
treatment
placebo
group
statist
signific
smd
ci
particip
cohen
smd
ci
particip
tavern
five
studi
object
measur
effect
nasal
decongest
one
hour
dose
akerlund
cohen
eccl
eccl
tavern
three
studi
report
effect
oral
nasal
decongest
compar
placebo
two
hour
treatment
cohen
latt
tavern
four
studi
report
effect
nasal
decongest
compar
placebo
three
hour
dose
akerlund
cohen
latt
tavern
ci
particip
report
statist
signific
differ
treatment
placebo
group
akerlund
report
effect
singl
dose
nasal
decongest
seven
hour
dose
studi
use
topic
decongest
show
small
differ
treatment
placebo
statist
signific
smd
ci
particip
gronborg
singledos
oral
decongest
studi
use
crossov
design
involv
particip
includ
metaanalys
gronborg
found
nar
worsen
placebo
group
wherea
improv
treatment
group
differ
statist
signific
p
four
multidos
studi
report
object
measur
nasal
congest
eccl
smd
ci
particip
jawad
smd
ci
particip
latt
smd
ci
particip
effect
multipl
dose
oral
decongest
object
measur
nasal
congest
statist
signific
four
studi
report
object
measur
nasal
congest
eccl
studi
use
topic
decongest
show
statist
signific
effect
multipl
dose
nasal
decongest
object
measur
nasal
congest
studi
express
least
squar
mean
nac
smd
ci
particip
smd
correspond
signific
clinic
effect
total
four
singledos
akerlund
cohen
latt
tavern
two
singledos
trial
report
advers
event
gronborg
tavern
use
oral
decongest
tavern
report
advers
event
either
treatment
placebo
group
result
gronborg
includ
metaanalysi
studi
use
crossov
studi
design
sever
event
per
patient
report
overal
event
report
treatment
placebo
group
respect
statist
signific
studi
report
specif
advers
event
howev
advers
event
differ
among
studi
rang
vomit
dri
mouth
lethargi
dizzi
pain
mouth
ulcer
latt
advers
event
clearli
describ
origin
paper
includ
cochran
review
author
tavern
therefor
use
number
review
well
report
specif
type
advers
event
report
one
studi
seven
studi
report
total
number
particip
advers
event
bye
eccl
eccl
eccl
eccl
latt
sperber
treatment
placebo
arm
particip
report
advers
event
chanc
advers
event
slightli
lower
treatment
group
particip
howev
differ
placebo
statist
signific
ci
particip
seven
studi
analysi
differ
studi
use
oral
topic
decongest
signific
p
pool
effect
advers
event
clear
heterogen
given
statist
use
randomeffect
model
throughout
analys
advers
event
chang
interpret
result
judg
evid
advers
event
low
qualiti
possibl
risk
bia
due
unclear
report
lack
precis
wide
confid
interv
differ
studi
use
oral
topic
decongest
signific
p
seem
moder
heterogen
given
statist
use
randomeffect
model
chang
interpret
result
six
studi
use
oral
decongest
report
total
number
particip
advers
event
pool
effect
advers
event
clear
heterogen
given
statist
use
randomeffect
model
analys
advers
event
chang
interpret
result
judg
evid
advers
event
moder
qualiti
possibl
risk
bia
due
unclear
report
clear
heterogen
given
statist
use
randomeffect
model
chang
interpret
result
eccl
use
topic
decongest
report
advers
event
studi
differ
treatment
placebo
statist
signific
ci
particip
none
studi
use
topic
decongest
report
insomnia
difficulti
sleep
eccl
use
topic
decongest
report
headach
advers
event
studi
differ
treatment
placebo
group
statist
signific
ci
particip
two
singledos
studi
report
advers
event
associ
oral
decongest
gronborg
tavern
tavern
report
event
gronborg
exclud
metaanalys
crossov
studi
therefor
combin
singledos
multidos
studi
result
result
multidos
advers
event
analysi
none
includ
studi
report
outcom
includ
singledos
trial
report
outcom
one
multidos
studi
report
time
full
recoveri
reineck
particip
reineck
use
topic
decongest
show
mean
time
full
recoveri
better
treatment
group
four
day
compar
placebo
group
six
day
p
includ
trial
report
outcom
plan
compar
studi
children
age
year
compar
age
year
howev
none
singledos
studi
includ
children
unabl
perform
subgroup
analysi
subgroup
analysi
specifi
priori
compar
oral
versu
nasal
decongest
sinc
unabl
pool
studi
could
perform
subgroup
analysi
howev
comparison
review
report
whether
oral
topic
decongest
use
plan
compar
studi
children
age
year
compar
age
year
howev
none
multidos
studi
includ
children
reineck
includ
peopl
age
year
exclud
children
multidos
studi
abl
pool
result
primari
outcom
subject
symptom
score
nasal
congest
three
studi
advers
event
seven
studi
therefor
assess
differ
oral
versu
topic
nasal
decongest
subject
symptom
score
nasal
congest
involv
two
studi
use
oral
decongest
sperber
tavern
one
use
topic
decongest
eccl
differ
studi
use
oral
decongest
studi
use
topic
decongest
statist
signific
p
also
advers
event
one
studi
use
topic
decongest
eccl
other
use
oral
decongest
bye
eccl
eccl
eccl
latt
sperber
differ
pool
result
oral
decongest
versu
studi
topic
decongest
statist
signific
p
plan
compar
studi
children
age
year
compar
age
year
howev
none
studi
includ
children
abl
assess
impact
oral
versu
topic
decongest
outcom
could
pool
result
singl
multidos
studi
avail
possibl
primari
outcom
subject
symptom
score
secondari
outcom
object
measur
nar
primari
outcom
subject
symptom
score
three
studi
report
mean
score
eccl
sperber
tavern
two
studi
report
auc
latt
latt
sinc
pool
two
outcom
measur
appropri
discuss
separ
studi
report
mean
subject
symptom
score
compar
pool
effect
two
studi
use
oral
decongest
sperber
tavern
result
one
studi
use
topic
decongest
eccl
differ
two
statist
signific
p
two
studi
use
auc
outcom
unabl
assess
differ
oral
topic
decongest
use
oral
decongest
oral
topic
decongest
statist
signific
p
howev
subgroup
includ
one
studi
multidos
decongest
indic
result
base
studi
use
oral
topic
decongest
result
report
detail
multipl
dose
decongest
monotherapi
use
common
cold
adult
prim
ari
outcom
e
subject
sym
ptom
score
auc
hour
af
ter
dose
oral
unstandardis
ean
auc
f
subject
sym
ptom
score
rang
f
rom
subject
nasal
congest
standard
unit
better
treatm
ent
group
ci
p
valu
compar
effect
nasal
decongest
administ
singl
multipl
dose
treat
nasal
congest
peopl
common
cold
includ
trial
analys
base
total
particip
nine
studi
use
pseudoephedrin
three
use
oxymetazolin
decongest
includ
phenylpropanolamin
norephedrin
xylometazolin
studi
use
phenylpropanolamin
norephedrin
exclud
metaanalys
drug
longer
avail
countri
fda
larg
differ
report
outcom
report
studi
method
limit
studi
therefor
pool
possibl
studi
studi
except
one
includ
adult
particip
age
year
reineck
includ
younger
peopl
age
year
provid
detail
mean
age
particip
result
review
applic
adult
unabl
draw
conclus
effect
singledos
decongest
pool
possibl
due
larg
divers
measur
report
symptom
congest
outcom
measur
overal
patient
wellb
time
recoveri
either
data
insuffici
data
avail
multipl
dose
decongest
metaanalysi
possibl
subject
measur
congest
measur
approxim
three
hour
last
dose
subject
measur
congest
significantli
better
treatment
group
particip
compar
placebo
group
particip
howev
clinic
effect
small
result
base
two
studi
one
topic
one
oral
decongest
involv
total
particip
henc
multipl
dose
nasal
decongest
seem
small
benefici
effect
nasal
congest
measur
subject
although
subject
measur
nasal
congest
probabl
relev
outcom
sinc
nasal
decongest
use
symptomat
relief
clear
small
effect
clinic
relev
suffici
justifi
widespread
use
decongest
tavern
insuffici
data
estim
differ
efficaci
oral
versu
topic
decongest
advers
event
report
nine
studi
risk
advers
event
treatment
group
particip
significantli
differ
peopl
placebo
group
seem
shortterm
use
nasal
decongest
adult
common
cold
consid
safe
recognis
includ
studi
addit
studi
heterogen
approach
outcom
measur
number
studi
could
pool
outcom
even
smaller
subgroup
analys
contain
two
studi
henc
generalis
result
limit
respect
advers
event
surpris
note
none
includ
multidos
studi
investig
problem
tachyphylaxi
rhiniti
medicamentosa
could
due
limit
followup
studi
one
day
furthermor
side
effect
profil
oral
versu
topic
decongest
might
differ
one
might
expect
system
delay
side
effect
oral
prepar
unabl
assess
aspect
one
studi
use
topic
decongest
report
advers
effect
twelv
studi
use
subject
measur
outcom
probabl
relev
outcom
clinic
applic
nasal
decongest
use
symptomat
relief
addit
studi
except
one
includ
particip
communityacquir
common
cold
result
applic
adult
popul
none
studi
includ
children
age
year
younger
anoth
concern
applic
current
evid
relat
use
pseudoephedrin
nine
studi
test
effect
pseudoephedrin
howev
avail
sinc
overthecount
decongest
use
make
methamphetamin
fda
current
pseudoephedrin
replac
phenylephrin
way
control
methamphetamin
abus
despit
phenylephrin
common
decongest
avail
overthecount
none
studi
review
evalu
effect
outcom
downgrad
qualiti
evid
moder
low
due
limit
data
avail
poor
risk
bia
assess
includ
studi
total
particip
pool
often
possibl
pool
possibl
result
often
base
two
studi
studi
except
one
includ
adult
particip
find
review
generalis
children
recognis
half
includ
studi
publish
mani
studi
provid
suffici
methodolog
inform
exclud
risk
bia
henc
studi
risk
bia
unclear
given
small
number
includ
studi
possibl
find
relev
trial
henc
public
bia
definit
rule
may
lead
overestim
treatment
effect
exampl
found
four
studi
relev
review
result
avail
two
complet
trial
publish
result
third
although
origin
regist
state
ongo
fourth
studi
also
ongo
start
estim
complet
date
recent
chang
april
may
review
conduct
outlin
cochran
handbook
systemat
review
intervent
higgin
search
sever
databas
three
author
ld
lg
nm
independ
select
studi
extract
data
thu
minimis
risk
introduc
bia
review
process
result
line
systemat
review
metaanalys
similar
older
cochran
review
nasal
decongest
common
cold
tavern
conclud
nasal
decongest
modestli
effect
shortterm
relief
congest
adult
two
hour
dose
signific
decreas
patientreport
symptom
treatment
versu
placebo
describ
similar
find
effect
small
although
statist
signific
clear
reduct
symptom
clinic
relev
suffici
justifi
widespread
use
decongest
tavern
sever
review
nasal
decongest
common
cold
also
publish
eg
allan
arrol
arrol
meltzer
gener
conclus
base
cochran
review
tavern
tavern
recent
studi
includ
review
accordingli
result
conclus
similar
line
review
kollar
investig
effect
singl
mg
dose
phenylephrin
compar
placebo
kollar
show
singl
oral
dose
phenylephrin
significantli
improv
acut
nasal
congest
howev
must
note
metaanalys
review
almost
complet
base
small
unpublish
studi
conduct
includ
monograph
us
food
drug
administr
fda
accord
eccl
studi
includ
fda
report
inhous
studi
provid
repres
pharmaceut
compani
eccl
anoth
review
xylometazolin
alon
combin
conclud
xylometazolin
provid
fast
effect
relief
nasal
congest
eccl
howev
review
includ
four
studi
includ
metaanalysi
includ
one
studi
use
xylometazolin
eccl
henc
unabl
formul
firm
conclus
effect
medic
furthermor
beyond
scope
review
evalu
effect
differ
nasal
decongest
individu
cochran
review
combin
drug
common
cold
oral
antihistaminedecongestantanalges
combin
found
effect
individu
symptom
small
probabl
small
clinic
relev
de
sutter
lack
evid
children
also
confirm
studi
decongest
alon
combin
product
allan
arrol
de
sutter
term
risk
side
effect
result
agreement
review
studi
incid
side
effect
shortterm
use
decongest
low
side
effect
mostli
mild
moder
eg
insomnia
headach
allan
eccl
tavern
although
identifi
data
safeti
nasal
decongest
children
report
advers
event
singl
use
nasal
decongest
exampl
fda
publish
warn
seriou
advers
event
ingest
overthecount
nasal
spray
contain
oxymetazolin
children
age
six
year
fda
effect
nasal
decongest
monotherapi
uncertain
may
small
benefit
subject
experi
nasal
congest
multipl
dose
nasal
decongest
lowqual
evid
howev
unclear
small
effect
clinic
relev
due
small
number
studi
use
topic
nasal
decongest
unabl
draw
conclus
effect
oral
versu
topic
decongest
incid
mostli
mildtomoder
side
effect
low
result
applic
adult
despit
common
cold
equal
common
children
evid
avail
either
effect
safeti
children
given
high
consumpt
nasal
decongest
surpris
littl
evid
avail
question
effect
safeti
children
remain
unansw
howev
given
report
seriou
advers
event
young
children
research
group
appear
warrant
feasibl
fda
question
regard
effect
safeti
nasal
decongest
adult
also
remain
unansw
research
need
investig
longterm
effect
multipl
dose
nasal
decongest
tachyphylaxi
rhiniti
medicamentosa
differ
oral
topic
decongest
need
explor
unabl
compar
effect
differ
decongest
exampl
pseudoephedrin
often
replac
phenylephrin
way
control
methamphetamin
abus
howev
decongest
phenylephrin
may
effect
eccl
despit
phenylephrin
common
decongest
avail
overthecount
none
includ
studi
evalu
effect
henc
largescal
goodqual
randomis
control
trial
evalu
effect
sever
nasal
decongest
need
furthermor
futur
research
seek
defin
minim
clinic
import
differ
measur
subject
improv
nasal
congest
avail
use
statist
approach
interpret
result
exampl
regard
standardis
mean
differ
small
effect
howev
remain
unclear
small
statist
effect
correspond
clinic
effect
wish
thank
sarah
thorn
assist
search
liz
dooley
support
review
process
also
wish
thank
laura
alder
assist
initi
select
studi
thank
ann
fonfa
dee
shneiderman
mark
jone
tim
keneali
bruce
arrol
help
comment
draft
review
method
randomis
doubleblind
placebocontrol
parallelgroup
studi
random
sequenc
gener
select
bia
low
risk
randomis
list
use
drug
alloc
separ
randomis
list
men
women
age
year
centr
list
balanc
number
arrang
everi
eight
person
list
alloc
conceal
select
bia
low
risk
drug
issu
code
bottl
drug
issu
patient
code
bottl
tablet
ident
appear
special
made
differ
appear
market
prepar
blind
particip
personnel
perform
bia
outcom
appear
tablet
ident
drug
issu
patient
code
bottl
tablet
ident
appear
special
made
differ
appear
market
prepar
howev
patient
also
ask
think
trial
tablet
took
placebo
patient
placebo
indic
thought
placebo
compar
treatment
group
blind
outcom
assess
detect
bia
outcom
unclear
risk
method
outcom
assess
blind
discuss
incomplet
outcom
data
attrit
bia
outcom
low
risk
incomplet
data
describ
tabl
number
remain
particip
per
treatment
group
provid
three
stop
take
tablet
complet
diari
unwant
side
effect
two
excess
drowsi
take
triprolidin
one
urticaria
develop
treatment
pseudoephedrin
reason
obtain
volunt
complet
diari
select
report
report
bia
high
risk
separ
result
primari
symptom
provid
signific
differ
sneez
discuss
bia
unclear
risk
fund
organis
describ
patient
cold
period
clear
particip
receiv
treatment
randomis
method
randomis
doubleblind
placebocontrol
parallelgroup
studi
particip
n
recruit
male
femal
n
analys
particip
focu
monotherapi
review
result
phenylpropanolamineonli
placebo
group
extract
randomis
ratio
clearli
state
assum
equal
number
differ
treatment
group
low
risk
treatment
placebo
prepar
look
ident
four
studi
prepar
given
identicallyappear
cherri
flavour
hydroalcohol
syrup
doubleblind
fashion
accord
randomis
code
blind
particip
personnel
perform
bia
outcom
low
risk
state
treatment
alloc
doubleblind
fashion
supervis
senior
scientist
four
studi
prepar
given
identicallyappear
cherri
flavour
hydroalcohol
syrup
doubleblind
fashion
accord
randomis
code
four
formul
code
randomis
alloc
prepar
supervis
mr
pregnant
lactat
clinic
histori
deem
physician
reason
exclus
ischaem
heart
diseas
angina
cardiac
arrhythmia
hypertens
histori
renal
failur
histori
perenni
allerg
rhiniti
patient
histori
season
allerg
rhiniti
exclud
patient
recruit
season
nasal
polyp
histori
benign
prostat
hypertrophi
histori
bacteri
sinus
previou
week
use
antibiot
prior
studi
entri
use
tricycl
antidepress
monoamin
oxidas
inhibitor
smoker
could
abstain
smoke
lab
visit
diagnost
criteria
patient
suffer
nasal
congest
due
upper
respiratori
tract
infect
score
moder
nasal
congest
scale
cold
symptom
began
within
hour
nasal
airway
resist
baselin
day
intervent
nasal
decongest
dose
sudaf
tablet
contain
mg
pseudoephedrin
hydrochlorid
match
placebo
tablet
administr
multipl
dose
oral
tablet
patient
instruct
take
tablet
time
day
everi
hour
day
followup
day
measur
total
nasal
airway
resist
measur
posterior
rhinomanometri
sampl
pressur
pa
baselin
everi
min
day
day
hour
dose
subject
nasal
congest
measur
mm
visual
analogu
scale
nose
complet
clear
nose
complet
block
symptom
nasal
congestionstuffi
nasal
dischargerunni
nose
score
ordin
scale
baselin
pm
day
outcom
primari
outcom
auc
nar
hour
first
dose
day
secondari
outcom
nasal
airway
resist
auc
hour
first
dose
day
nasal
airway
resist
auc
hour
last
dose
day
nasal
congest
measur
symptom
scale
auc
hour
first
dose
day
last
dose
day
mean
chang
baselin
nasal
stuffi
runni
nose
score
day
note
fund
pfizer
consum
healthcar
declar
interest
provid
one
author
employ
pfizer
random
sequenc
gener
select
bia
low
risk
randomis
code
use
medic
randomis
code
prepar
pfizer
consum
healthcar
alloc
conceal
select
bia
low
risk
conceal
disclosur
envelop
use
placebo
match
treatment
ident
treatment
kit
conceal
disclosur
envelop
open
case
emerg
alloc
medic
stratifi
accord
baselin
nasal
airway
resist
low
nasal
airway
resist
high
nasal
airway
resist
studi
medic
consist
mg
pseudoephedrin
match
placebo
tablet
blind
particip
personnel
perform
bia
outcom
low
risk
patient
receiv
match
placebo
tablet
ensur
participantspersonnel
knowledg
intervent
alloc
studi
medic
consist
mg
pseudoephedrin
match
placebo
tablet
blind
outcom
assess
detect
bia
outcom
unclear
risk
method
outcom
assess
blind
discuss
incomplet
outcom
data
attrit
bia
outcom
unclear
risk
number
miss
valu
describ
howev
clear
mani
person
remain
group
particip
recruit
protocolvalid
day
protocolvalid
day
miss
predos
assess
imput
correspond
auc
set
miss
miss
data
auc
imput
either
read
miss
select
report
report
bia
low
risk
outcom
report
bia
unclear
risk
studi
fund
pfizer
method
randomis
doubleblind
placebocontrol
parallelgroup
studi
particip
n
recruit
patient
screen
randomis
n
analys
unclear
text
presum
use
paracetamol
pseudoephedrin
paracetamol
pseudoephedrin
placebo
focu
monotherapi
review
result
treatment
group
pseudoephedrin
placebo
extract
age
older
countri
uk
inclus
criteria
patient
gener
good
health
least
year
old
exclus
criteria
nasal
resist
within
normal
rang
screen
histori
allerg
rhiniti
chronic
respiratori
diseas
anatom
nasal
obstruct
deform
presenc
nasal
polyp
diseas
contraind
use
either
paracetamol
pseudoephedrin
patient
taken
certain
medic
within
given
timescal
studi
entri
also
exclud
astemizol
day
monoamin
oxidas
inhibitor
day
antibiot
day
antihistamin
hour
analges
antipyret
hour
nasal
decongest
hour
antituss
medic
lozeng
throat
spray
hour
alcohol
hour
menthol
product
hour
patient
use
metoclopramid
domperidon
cholestyramin
anticoagul
therapi
also
exclud
studi
diagnost
criteria
symptomat
upper
respiratori
tract
infect
day
durat
nasal
congest
ie
total
nasal
airflow
resist
determin
posterior
rhinomanometri
pain
least
moder
intens
baselin
intervent
nasal
decongest
dose
mg
paracetamol
combin
mg
pseudoephedrin
mg
paracetamol
alon
mg
pseudoephedrin
alon
placebo
administr
multipl
dose
oral
medic
singl
dose
given
clinic
patient
instruct
dose
requir
time
per
day
minimum
dose
interv
hour
day
followup
day
measur
nasal
airflow
conduct
calcul
measur
nasal
resist
airflow
fix
sampl
nasal
pressur
pa
use
posterior
rhinomanometri
pain
relief
cold
flulik
symptom
composit
sore
throat
headach
bodi
ach
pain
assess
use
verbal
rate
scale
none
littl
lot
complet
relief
pain
intens
composit
sore
throat
headach
bodi
ach
pain
nasal
congest
scale
none
mild
moder
sever
global
assess
pain
relief
nasal
congest
relief
followup
visit
scale
poor
fair
good
good
excel
advers
event
record
assess
nasal
airflow
resist
pain
relief
intens
made
hour
dose
patient
assess
nasal
congest
pain
intens
even
outcom
primari
outcom
nasal
airflow
conduct
pain
relief
secondari
outcom
advers
event
note
fund
glaxosmithklin
declar
interest
studi
fund
glaxosmithklin
plc
dr
mn
ej
ib
employe
glaxosmithklin
plc
act
consult
glaxosmithklin
plc
random
sequenc
gener
select
bia
low
risk
randomis
schedul
use
elig
patient
assign
treatment
regimen
combin
paracetamol
alon
pseudoephedrin
alon
placebo
equal
ratio
accord
parallel
group
randomis
schedul
alloc
conceal
select
bia
unclear
risk
method
alloc
conceal
describ
blind
particip
personnel
perform
bia
outcom
low
risk
studi
state
doubleblind
doubledummi
method
use
blind
outcom
assess
detect
bia
outcom
unclear
risk
studi
state
doubleblind
mention
method
blind
outcom
assess
incomplet
outcom
data
attrit
bia
outcom
number
discontinu
per
treatment
group
describ
patient
withdrew
due
advers
event
singl
dose
phase
studi
multipl
dose
phase
patient
dri
mouth
combin
treatment
vomitingpseudoephedrin
treatment
discontinu
dose
due
advers
event
select
report
report
bia
low
risk
intend
outcom
report
bia
unclear
risk
studi
fund
glaxosmithklin
plc
method
randomis
doubleblind
placebocontrol
parallelgroup
studi
particip
n
recruit
screen
meet
inclus
criteria
randomis
dose
n
analys
xylometazolin
n
placebo
n
age
year
median
age
countri
uk
inclus
criteria
age
year
male
patient
nonpregn
nonlact
femal
patient
recent
onset
nasal
congest
due
common
cold
cold
symptom
hour
studi
entri
exclus
criteria
inabl
abstain
smoke
hour
durat
visit
nar
screen
visit
histori
perenni
allerg
rhiniti
unless
recruit
season
signific
abnorm
eg
polyp
deviat
septum
histori
transsphenoid
hypophysectomi
rhiniti
medicamentosa
bacteri
sinus
infect
past
week
studi
entri
use
drug
antibiot
alphaadrenerg
glucocorticosteroid
antidepress
monoamin
oxidas
inhibitor
use
medic
may
affect
sleep
judg
investig
known
hypersensit
xylometazolin
excipi
otrivin
nasal
spray
alcohol
intak
uncontrol
arteri
hypertens
diagnost
criteria
minimum
nasal
congest
score
rate
scale
present
mild
moder
sever
minimum
common
cold
symptom
runni
nose
block
nose
sore
throat
cough
nasal
decongest
dose
xylometazolin
mgml
metereddos
nasal
spray
placebo
salin
solut
administr
multipl
dose
nasal
spray
spray
g
nostril
time
per
day
total
common
cold
symptom
score
record
maximum
day
followup
clear
maximum
day
measur
nasal
airway
resist
measur
use
activ
posterior
rhinomanometri
baselin
min
hour
dose
subject
symptom
score
visual
analogu
scale
nose
complet
clear
nose
complet
block
measur
everi
min
min
period
runni
nose
block
nose
sore
throat
cough
sneez
ear
ach
score
record
everi
day
scale
present
mild
moder
sever
measur
subject
measur
sleep
tired
daili
activ
gener
wellb
smell
advers
event
record
outcom
primari
outcom
total
nasal
airway
resist
secondari
outcom
time
onset
subject
relief
nasal
congest
peak
subject
relief
nasal
congest
lowest
score
symptom
common
cold
runni
nose
block
nose
sore
throat
cough
sneez
ear
ach
score
record
scale
fund
novarti
declar
interest
eriksson
graffera
sc
chen
employe
novarti
clinic
trial
sponsor
novarti
random
sequenc
gener
select
bia
unclear
risk
method
randomis
clearli
describ
elig
patient
randomis
ratio
treat
doubleblind
alloc
conceal
select
bia
unclear
risk
clear
particip
could
forese
treatment
alloc
sinc
stratifi
accord
sever
nasal
congest
patient
stratifi
accord
sever
nasal
congest
measur
posterior
rhinomanometri
screen
first
studi
visit
nasal
airway
resist
per
second
nasal
spray
devic
ident
deliv
gactuat
blind
particip
personnel
perform
bia
outcom
low
risk
state
treatment
administ
doubleblind
nasal
spray
devic
ident
deliv
gactuat
blind
outcom
assess
detect
bia
outcom
unclear
risk
method
blind
outcom
assess
discuss
incomplet
outcom
data
attrit
bia
outcom
low
risk
incomplet
outcom
data
describ
number
remain
particip
per
treatment
group
provid
tabl
patient
randomis
studi
randomis
dose
either
return
day
treatment
n
return
unabl
reproduc
techniqu
requir
measur
nasal
airway
resist
n
patient
includ
intentiontotreat
efficaci
safeti
analysi
select
report
report
bia
high
risk
outcom
report
total
nasal
airway
resist
mention
primari
outcom
total
nasal
airway
conduct
report
baselin
tabl
investig
differenti
nasal
resist
nasal
conduct
result
nasal
conduct
report
bia
unclear
risk
fund
novarti
method
randomis
doubleblind
placebocontrol
parallelgroup
studi
particip
n
recruit
n
analys
withdrew
consent
focu
monotherapi
review
result
treatment
group
pseudoephedrin
placebo
extract
number
patient
per
treatment
group
provid
percentag
advers
event
calcul
follow
number
aspirin
pseudoephedrin
n
aspirin
n
pseudoephedrin
n
placebo
n
age
state
countri
uk
inclus
criteria
nasal
congest
pain
associ
upper
respiratori
tract
infect
day
exclus
criteria
allerg
rhiniti
chronic
respiratori
diseas
hyperthyroid
cardiovascular
diseas
sever
hypertens
peptic
ulcer
hypersensit
acetylsalicyl
acid
aspirin
pseudoephedrin
medic
allow
prior
studi
entri
monoamineoxidas
inhibitor
day
antihistamin
antibiot
day
analges
antipyret
eccl
continu
hour
nasal
decongest
hour
lozeng
throat
spray
hour
menthol
contain
product
hour
patient
anticoagul
therapi
pregnant
lactat
femal
also
exclud
studi
diagnost
criteria
pain
score
least
moder
intens
scale
total
nasal
airway
resist
determin
posterior
rhinomanometri
nasal
decongest
dose
mg
aspirin
mg
pseudoephedrin
mg
aspirin
mg
pseudoephedrin
placebo
administr
multipl
dose
sachet
small
dispos
bag
granul
dissolv
water
taken
oral
dose
per
day
day
minimum
dose
interv
hour
followup
day
measur
pain
symptom
score
composit
score
sore
throat
andor
headach
record
categor
scale
consist
pain
mild
pain
moder
pain
sever
pain
nasal
obstruct
total
nasal
air
flow
resist
determin
posterior
rhinomanometri
measur
hour
dose
even
everi
day
patient
ask
assess
pain
intens
pain
relief
nasal
congest
intens
nasal
congest
relief
day
ask
global
assess
pain
relief
global
assess
nasal
congest
relief
advers
event
record
whole
studi
period
unclear
risk
method
randomis
sequenc
gener
discuss
alloc
conceal
select
bia
low
risk
particip
could
forese
treatment
alloc
sinc
differ
treatment
appear
tast
smell
doubl
blind
guarante
sinc
possibl
distinguish
combin
product
monotherapi
placebo
granul
treatment
dispens
sachet
contain
white
granul
dissolv
water
appear
tast
notic
smell
neither
investig
patient
awar
natur
treatment
therefor
blind
assess
placebo
contain
flavour
excipi
present
medic
sucros
hypromellos
binder
orang
flavour
citric
acid
blind
particip
personnel
perform
bia
outcom
investig
state
doubleblind
guarante
doubl
blind
guarante
sinc
possibl
distinguish
combin
product
monotherapi
placebo
granul
treatment
dispens
sachet
contain
white
granul
dissolv
water
appear
tast
notic
smell
neither
investig
patient
awar
natur
treatment
therefor
blind
assess
placebo
contain
flavour
excipi
present
medic
sucros
hypromellos
binder
orang
flavour
citric
acid
blind
outcom
assess
detect
bia
outcom
low
risk
neither
investig
patient
awar
natur
treatment
therefor
blind
assess
incomplet
outcom
data
attrit
bia
outcom
unclear
risk
miss
data
describ
howev
clear
mani
patient
remain
treatment
group
patient
randomis
patient
randomis
studi
treat
particip
withdrew
consent
particip
includ
analys
select
report
report
bia
low
risk
primari
secondari
outcom
measur
report
bia
unclear
risk
studi
sponsor
bayer
healthcar
llc
number
particip
group
provid
method
sampl
size
calcul
provid
yield
total
sampl
size
approxim
patient
randomis
aspirin
pseudoephedrin
combin
aspirin
alon
pseudoephedrin
alon
group
patient
randomis
placebo
group
wherea
eventu
randomis
method
randomis
doubleblind
placebocontrol
crossov
design
particip
n
recruit
n
analys
four
subject
exclud
becam
evid
second
day
cold
symptom
disappear
countri
denmark
age
rang
year
mean
age
year
inclus
criteria
nose
blow
least
ml
could
provid
observ
period
exclus
criteria
none
state
four
subject
exclud
becam
evid
second
day
cold
symptom
disappear
diagnost
criteria
sudden
occurr
sneez
nasal
discharg
blockag
least
symptom
nasal
symptom
last
hour
student
felt
sure
hesh
caught
cold
investig
observ
sign
cold
nasal
voic
sneez
nose
blow
min
observ
period
intervent
nasal
decongest
dose
singl
dose
mg
norephedrin
sustain
releas
form
administr
singl
dose
oral
tablet
crossov
design
particip
receiv
treatment
day
placebo
anoth
day
followup
day
measur
nasal
airway
resist
measur
posterior
rhinomanometri
nasal
peak
flow
measur
immedi
rhinomanometri
use
write
peak
flow
minimet
measur
hour
treatment
selfassess
test
nasal
blockag
scale
complet
free
complet
blockag
record
number
sneez
nose
blow
per
hour
measur
hourli
hour
treatment
side
effect
questionnair
new
symptom
outcom
studi
explicitli
state
measur
outcom
primari
secondari
assum
follow
primari
outcom
nasal
airway
resist
nasal
peak
flow
selfassess
nasal
blockag
secondari
outcom
number
sneez
nose
blow
per
hour
side
effect
note
fund
h
lundbeck
co
fund
studi
provid
medic
declar
interest
provid
random
sequenc
gener
select
bia
unclear
risk
method
randomis
describ
student
got
singl
dose
mg
norephedrin
sustain
releas
form
placebo
randomis
order
alloc
conceal
select
bia
unclear
risk
mention
alloc
conceal
describ
due
crossov
design
patient
enrol
studi
receiv
treatment
placebo
blind
particip
personnel
perform
bia
outcom
low
risk
studi
report
doubleblind
tablet
suppli
code
vial
h
lundbeck
co
copenhagen
denmark
blind
outcom
assess
detect
bia
outcom
low
risk
studi
report
doubleblind
rhinomanometri
read
valu
depend
degre
upon
investig
interpret
curv
order
elimin
po
patient
nasal
congest
associ
histori
common
cold
less
hour
exclus
criteria
anatom
nasal
obstruct
gross
anatom
deform
includ
moder
sever
deviat
septum
presenc
nasal
polyp
taken
menthol
lozeng
menthol
contain
product
past
hour
taken
nasal
decongest
past
hour
taken
antihistamin
last
hour
astemizol
last
day
taken
analges
last
hour
taken
prescrib
medic
within
last
day
except
contracept
pill
histori
hyperthyroid
diabet
mellitu
heart
diseas
prostat
hypertrophi
hypertens
diagnost
criteria
subject
score
moder
block
nose
least
mild
cold
symptom
patient
screen
physician
medic
histori
taken
blood
pressur
puls
measur
intervent
nasal
decongest
dose
pseudoephedrin
mg
tablet
placebo
sanatogen
multivitamin
tablet
administr
multipl
dose
oral
tablet
dose
day
interv
followup
day
measur
unilater
nasal
airflow
measur
use
posterior
rhinomanometri
inspiratori
refer
pressur
pa
oral
cannula
sens
posterior
nasal
pressur
measur
hour
first
dose
medic
everi
hour
period
studi
nasal
patenc
express
term
nasal
airflow
refer
pressur
pa
rather
nasal
resist
nasal
resist
tend
toward
infin
nasal
obstruct
wherea
nasal
airflow
tend
toward
zero
assum
nasal
airway
conduct
patient
ask
score
common
cold
symptom
cough
runni
nose
block
nose
sore
throat
box
scale
symptom
label
present
mild
moder
sever
sever
acoust
rhinometri
activ
posterior
rhinomanometri
pa
subject
rate
nasal
congest
measur
mm
visual
analogu
scale
anchor
descriptor
nose
complet
clear
mm
nose
complet
block
mm
baselin
measur
conduct
min
interv
hour
follow
dose
studi
treatment
posttreat
hour
serial
measur
undertaken
min
interv
outcom
primari
outcom
total
volum
total
minimum
crosssect
area
insid
nasal
caviti
secondari
outcom
nasal
airway
resist
visual
analogu
scale
percept
congest
note
fund
sourc
fund
provid
treatment
medic
mg
sudafedtm
tablet
pfizer
consum
healthcar
group
caringbah
nsw
australia
declar
interest
provid
random
sequenc
gener
select
bia
low
risk
treatment
randomis
random
number
tabl
block
four
alloc
conceal
select
bia
low
risk
conceal
treatment
alloc
pseudoephedrin
placebo
place
ident
opaqu
gelatin
capsul
blind
particip
personnel
perform
bia
outcom
low
risk
pseudoephedrin
placebo
place
ident
opaqu
gelatin
capsul
blind
outcom
assess
detect
bia
outcom
total
nasal
airway
resist
measur
use
posterior
rhinomanometri
techniqu
total
nasal
volum
total
minimum
crosssect
area
measur
use
acoust
rhinometri
mm
visual
analogu
scale
mm
mm
use
assess
symptom
nasal
congest
subject
measur
categor
scale
previou
hour
none
incapacit
worst
level
congest
worst
level
nasal
discharg
worst
level
sneez
measur
perform
hourli
hour
first
dose
day
last
dose
day
outcom
primari
outcom
area
logarithmtransform
total
nasal
airway
resist
curv
hour
first
dose
studi
medic
day
secondari
outcom
area
curv
total
minimum
crosssect
area
combin
left
right
nasal
caviti
hour
day
area
curv
total
nasal
volum
combin
left
right
nasal
caviti
hour
day
area
curv
nasal
congest
visual
analogu
scale
hour
day
rct
randomis
control
trial
screen
eg
isocarboxazid
marplan
phenelzin
nardil
selegilin
eldepryl
emsam
zelapar
tranylcypromin
parnat
note
particip
may
discontinu
take
maoi
sole
purpos
qualifi
studi
known
sensit
allergi
pseudoephedrin
phenylephrin
acetaminophen
excipi
drug
product
taken
oral
cold
allergi
medicin
within
hour
enrol
intranas
decongest
within
hour
enrol
except
singleingredi
overthecount
analges
need
take
addit
medic
includ
cough
cold
ie
oral
intranas
antihistamin
intranas
steroid
intranas
decongest
herbaldietari
supplement
studi
except
acetaminophen
medic
regimen
hyperexcit
disord
stabl
least
month
daili
vitamin
multivitaminmultiminer
supplement
particip
anoth
clinic
studi
within
day
entri
anoth
child
household
current
particip
studi
histori
drug
alcohol
tobacco
use
older
children
involv
directli
indirectli
conduct
administr
studi
ie
children
princip
investig
subinvestig
studi
coordin
studi
personnel
employe
perrigo
famili
temporari
relief
nasal
congest
due
pseudoephedrin
versu
placebo
outcom
primari
outcom
nasal
congest
sever
instantan
score
day
weight
sum
chang
baselin
nasal
congest
sever
instantan
score
first
hour
treatment
day
secondari
outcom
chang
baselin
nasal
congest
sever
instantan
score
hour
day
sum
chang
baselin
nasal
congest
sever
instantan
score
hour
first
dose
day
chang
baselin
nasal
congest
sever
instantan
score
hour
day
weight
sum
chang
baselin
nasal
congest
sever
score
instantan
hour
first
dose
day
nasal
congest
relief
reflect
score
hour
hour
day
sum
nasal
congest
relief
reflect
score
hour
hour
day
nasal
congest
sever
score
instantan
score
time
point
hour
day
nasal
congest
sever
score
instantan
score
time
point
hour
first
dose
day
nasal
congest
relief
reflect
score
hour
hour
day
sum
nasal
congest
relief
reflect
score
hour
hour
day
nasal
congest
relief
reflect
score
hour
day
nasal
congest
relief
reflect
score
hour
day
total
event
nasal
decongest
placebo
heterogen
tau
chi
df
p
test
overal
effect
z
p
test
subgroup
differ
chi
df
p
favour
placebo
favour
nasal
decongest
object
nar
auc
review
nasal
decongest
monotherapi
common
cold
heterogen
tau
chi
df
p
test
overal
effect
z
p
disciplin
gener
practic
australia
sourc
support
suppli
review
differ
protocol
ta
follow
section
method
data
collect
analysi
unit
analysi
issu
specifi
handl
data
trial
includ
one
treatment
arm
treatment
arm
similar
eg
differ
dose
nasal
decongest
combin
data
treatment
arm
compar
group
control
group
recommend
section
tabl
cochran
handbook
systemat
review
intervent
higgin
ad
randomis
crossov
trial
inclus
criteria
crossov
studi
adequ
randomis
regard
rct
also
specifi
handl
data
trial
use
crossov
design
result
studi
includ
metaanalysi
report
narr
method
data
collect
analysi
data
synthesi
specifi
ruleofthumb
effect
size
facilit
interpret
smd
describ
section
cochran
handbook
systemat
review
intervent
higgin
section
also
ad
descript
assess
overal
qualiti
evid
use
grade
grade
recommend
assess
develop
evalu
approach
give
indic
confid
place
estim
treatment
effect
effect
estim
grade
rate
summaris
summari
find
tabl
summaris
result
one
studi
avail
use
gradeprofil
tool
gradepro
follow
advic
grade
handbook
also
analys
singl
multidos
studi
togeth
wherea
protocol
state
would
analys
separ
ta
clinic
could
argu
singl
multipledos
nasal
decongest
would
similar
effect
although
may
long
last
singl
dose
expect
three
hour
dose
effect
singl
dose
clinic
expect
inferior
multipl
dose
therefor
combin
singl
multipl
dose
three
hour
dose
base
feedback
statist
editor
decid
use
randomeffect
model
metaanalys
nevertheless
report
whether
use
fixedeffect
randomeffect
model
affect
result
see
method
data
collect
analysi
data
synthesi
